Globus Medical, Inc. (NYSE:GMED) is Global Alpha Capital Management Ltd.’s 3rd Largest Position

Global Alpha Capital Management Ltd. lessened its holdings in Globus Medical, Inc. (NYSE:GMED) by 7.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 819,391 shares of the medical device company’s stock after selling 65,750 shares during the period. Globus Medical makes up about 4.9% of Global Alpha Capital Management Ltd.’s investment portfolio, making the stock its 3rd largest position. Global Alpha Capital Management Ltd. owned about 0.60% of Globus Medical worth $67,772,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the business. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Globus Medical by 2.5% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 5,637 shares of the medical device company’s stock worth $403,000 after purchasing an additional 140 shares during the period. Stephens Inc. AR lifted its position in Globus Medical by 3.4% in the third quarter. Stephens Inc. AR now owns 4,229 shares of the medical device company’s stock worth $303,000 after buying an additional 138 shares during the last quarter. Farther Finance Advisors LLC boosted its stake in Globus Medical by 230.5% during the third quarter. Farther Finance Advisors LLC now owns 552 shares of the medical device company’s stock worth $39,000 after buying an additional 385 shares during the period. Van ECK Associates Corp boosted its stake in Globus Medical by 36.1% during the third quarter. Van ECK Associates Corp now owns 62,505 shares of the medical device company’s stock worth $4,618,000 after buying an additional 16,583 shares during the period. Finally, Crossmark Global Holdings Inc. increased its position in Globus Medical by 6.0% during the third quarter. Crossmark Global Holdings Inc. now owns 7,750 shares of the medical device company’s stock valued at $554,000 after acquiring an additional 436 shares during the last quarter. Institutional investors own 95.16% of the company’s stock.

Globus Medical Stock Up 1.5 %

Shares of NYSE GMED opened at $77.48 on Friday. Globus Medical, Inc. has a twelve month low of $49.33 and a twelve month high of $94.93. The firm has a market cap of $10.66 billion, a PE ratio of 103.31, a price-to-earnings-growth ratio of 1.61 and a beta of 1.19. The business has a fifty day simple moving average of $85.90 and a two-hundred day simple moving average of $79.63.

Globus Medical (NYSE:GMED) last announced its quarterly earnings results on Thursday, February 20th. The medical device company reported $0.84 EPS for the quarter, beating the consensus estimate of $0.74 by $0.10. Globus Medical had a return on equity of 10.83% and a net margin of 4.09%. The firm had revenue of $657.29 million for the quarter, compared to analyst estimates of $646.19 million. On average, research analysts expect that Globus Medical, Inc. will post 3.44 earnings per share for the current year.

Analyst Upgrades and Downgrades

GMED has been the subject of several analyst reports. BTIG Research raised their target price on shares of Globus Medical from $87.00 to $91.00 and gave the stock a “buy” rating in a report on Thursday, December 12th. StockNews.com downgraded shares of Globus Medical from a “buy” rating to a “hold” rating in a research note on Wednesday. Needham & Company LLC reaffirmed a “hold” rating on shares of Globus Medical in a research note on Friday, February 21st. Wells Fargo & Company reduced their price target on Globus Medical from $95.00 to $93.00 and set an “overweight” rating on the stock in a report on Friday, February 21st. Finally, Canaccord Genuity Group boosted their price objective on Globus Medical from $92.00 to $101.00 and gave the company a “buy” rating in a report on Friday, January 10th. Four investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Globus Medical currently has an average rating of “Moderate Buy” and an average price target of $97.82.

Insider Activity

In other Globus Medical news, CFO Keith W. Pfeil sold 14,167 shares of the stock in a transaction on Friday, January 10th. The stock was sold at an average price of $88.29, for a total transaction of $1,250,804.43. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 18.54% of the company’s stock.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.